Long Non-coding RNA PCAT1 Drives Clear Cell Renal Cell Carcinoma by Upregulating YAP Via Sponging MiR-656 and MiR-539

Overview

Journal Cell Cycle

Specialty Cell Biology

Date 2020 Apr 15

PMID 32286142

Citations 11

Authors

Rui Wang

Bin Zheng

Hongyan Liu

Xiuxian Wan

Affiliations

Soon will be listed here.

Abstract

Clear cell renal cell carcinoma (ccRCC) is the most common RCC subtype with high metastasis, poor prognosis and conventional chemotherapy resistance. Prostate cancer associated transcript 1 (PCAT1) is an important lncRNA that was reported to be involved in cell proliferation, migration and invasion of several types of cancer cells. However, its role in ccRCC is still undetermined. This study found that PCAT1 levels were elevated in ccRCC tumors as well as several ccRCC cells, and knockdown of PCAT1 with siRNA (si-PCAT1) alleviated cell proliferation, migration and invasion of Caki-2 and ACHN cells. With bioinformatics analysis, dual-luciferase reported assay, RNA pull-down assay and Spearman's correlation analysis, we demonstrated that PCAT1 acted as a sponge for miR-656 and miR-539. Moreover, we found dual competitive interaction of miR-656/539 with PCAT1 and yes-associated protein (YAP), resulting in the identification of PCAT1-miR-656/539-YAP axis in Caki-2 and ACHN cells. With CCK-8 assay and transwell assay, miR-656/539 inhibitor or YAP overexpression could alleviate the effects of si-PCAT1 on the proliferation, migration and invasion of Caki-2 and ACHN cells. Our data indicated that PCAT1 promotes proliferation, migration and invasion of ccRCC cells by upregulating YAP via sponging miR-656 and miR-539. Taken together, this study provided a novel therapeutic target for ccRCC treatment.

Citing Articles

Circulating exosomal PCAT1 as a complement of carcinoembryonic antigen for early colorectal cancer diagnosis.

Cao J, Chao W, Zhang J, Mao J, Zeng J, Luo D Heliyon. 2024; 10(20):e39264.

PMID: 39640681 PMC: 11620264. DOI: 10.1016/j.heliyon.2024.e39264.

Wang S, Qi X, Liu D, Xie D, Jiang B, Wang J Comput Struct Biotechnol J. 2024; 23:491-505.

PMID: 38249783 PMC: 10796827. DOI: 10.1016/j.csbj.2023.12.016.

A review on the role of long non-coding RNA and microRNA network in clear cell renal cell carcinoma and its tumor microenvironment.

Zhang Q, Ren H, Ge L, Zhang W, Song F, Huang P Cancer Cell Int. 2023; 23(1):16.

PMID: 36732762 PMC: 9893571. DOI: 10.1186/s12935-023-02861-6.

Renal cell carcinoma-derived exosomes deliver lncARSR to induce macrophage polarization and promote tumor progression via STAT3 pathway.

Zhang W, Zheng X, Yu Y, Zheng L, Lan J, Wu Y Int J Biol Sci. 2022; 18(8):3209-3222.

PMID: 35637970 PMC: 9134902. DOI: 10.7150/ijbs.70289.

TFAP2C-Mediated lncRNA PCAT1 Inhibits Ferroptosis in Docetaxel-Resistant Prostate Cancer Through c-Myc/miR-25-3p/SLC7A11 Signaling.

Jiang X, Guo S, Xu M, Ma B, Liu R, Xu Y Front Oncol. 2022; 12:862015.

PMID: 35402284 PMC: 8985761. DOI: 10.3389/fonc.2022.862015.

References

Qi P, Du X . The long non-coding RNAs, a new cancer diagnostic and therapeutic gold mine. Mod Pathol. 2012; 26(2):155-65. DOI: 10.1038/modpathol.2012.160. View

Gong J, Maia M, Dizman N, Govindarajan A, Pal S . Metastasis in renal cell carcinoma: Biology and implications for therapy. Asian J Urol. 2017; 3(4):286-292. PMC: 5730828. DOI: 10.1016/j.ajur.2016.08.006. View

Wang X, Li M, Wang Z, Han S, Tang X, Ge Y . Silencing of long noncoding RNA MALAT1 by miR-101 and miR-217 inhibits proliferation, migration, and invasion of esophageal squamous cell carcinoma cells. J Biol Chem. 2014; 290(7):3925-35. PMC: 4326802. DOI: 10.1074/jbc.M114.596866. View

Jiang H, Liang M, Jiang Y, Zhang T, Mo K, Su S . The lncRNA TDRG1 promotes cell proliferation, migration and invasion by targeting miR-326 to regulate MAPK1 expression in cervical cancer. Cancer Cell Int. 2019; 19:152. PMC: 6544966. DOI: 10.1186/s12935-019-0872-4. View

Huang J, Deng G, Liu T, Chen W, Zhou Y . Long noncoding RNA PCAT-1 acts as an oncogene in osteosarcoma by reducing p21 levels. Biochem Biophys Res Commun. 2018; 495(4):2622-2629. DOI: 10.1016/j.bbrc.2017.12.157. View

Gao P, Xia J, Sipeky C, Dong X, Zhang Q, Yang Y . Biology and Clinical Implications of the 19q13 Aggressive Prostate Cancer Susceptibility Locus. Cell. 2018; 174(3):576-589.e18. PMC: 6091222. DOI: 10.1016/j.cell.2018.06.003. View

Ren Y, Shang J, Li J, Liu W, Zhang Z, Yuan J . The long noncoding RNA links the microRNA miR-215 to oncogene CRKL-mediated signaling in hepatocellular carcinoma. J Biol Chem. 2017; 292(43):17939-17949. PMC: 5663891. DOI: 10.1074/jbc.M116.773978. View

Beermann J, Piccoli M, Viereck J, Thum T . Non-coding RNAs in Development and Disease: Background, Mechanisms, and Therapeutic Approaches. Physiol Rev. 2016; 96(4):1297-325. DOI: 10.1152/physrev.00041.2015. View

Lin C, Yang L . Long Noncoding RNA in Cancer: Wiring Signaling Circuitry. Trends Cell Biol. 2017; 28(4):287-301. PMC: 5869122. DOI: 10.1016/j.tcb.2017.11.008. View

10.

Guo H, Ahmed M, Zhang F, Yao C, Li S, Liang Y . Modulation of long noncoding RNAs by risk SNPs underlying genetic predispositions to prostate cancer. Nat Genet. 2016; 48(10):1142-50. DOI: 10.1038/ng.3637. View

11.

Huarte M . The emerging role of lncRNAs in cancer. Nat Med. 2015; 21(11):1253-61. DOI: 10.1038/nm.3981. View

12.

Zhang X, George J, Deb S, Degoutin J, Takano E, Fox S . The Hippo pathway transcriptional co-activator, YAP, is an ovarian cancer oncogene. Oncogene. 2011; 30(25):2810-22. DOI: 10.1038/onc.2011.8. View

13.

Batista P, Chang H . Long noncoding RNAs: cellular address codes in development and disease. Cell. 2013; 152(6):1298-307. PMC: 3651923. DOI: 10.1016/j.cell.2013.02.012. View

14.

Zender L, Spector M, Xue W, Flemming P, Cordon-Cardo C, Silke J . Identification and validation of oncogenes in liver cancer using an integrative oncogenomic approach. Cell. 2006; 125(7):1253-67. PMC: 3026384. DOI: 10.1016/j.cell.2006.05.030. View

15.

Wang X, Ren Y, Yang X, Xiong X, Han S, Ge Y . miR-190a inhibits epithelial-mesenchymal transition of hepatoma cells via targeting the long non-coding RNA treRNA. FEBS Lett. 2015; 589(24 Pt B):4079-87. DOI: 10.1016/j.febslet.2015.11.024. View

16.

Orom U, Derrien T, Beringer M, Gumireddy K, Gardini A, Bussotti G . Long noncoding RNAs with enhancer-like function in human cells. Cell. 2010; 143(1):46-58. PMC: 4108080. DOI: 10.1016/j.cell.2010.09.001. View

17.

Martens-Uzunova E, Bottcher R, Croce C, Jenster G, Visakorpi T, Calin G . Long noncoding RNA in prostate, bladder, and kidney cancer. Eur Urol. 2013; 65(6):1140-51. DOI: 10.1016/j.eururo.2013.12.003. View

18.

Hu X, Chen J, Fu Q . Downregulation of YAP in Clear Cell Renal Cell Carcinoma Contributes to Poor Prognosis and Progressive Features. Ann Clin Lab Sci. 2017; 47(1):36-39. View

19.

Ge Y, Yan X, Jin Y, Yang X, Yu X, Zhou L . MiRNA-192 [corrected] and miRNA-204 Directly Suppress lncRNA HOTTIP and Interrupt GLS1-Mediated Glutaminolysis in Hepatocellular Carcinoma. PLoS Genet. 2015; 11(12):e1005726. PMC: 4692503. DOI: 10.1371/journal.pgen.1005726. View

20.

Yang L, Lin C, Jin C, Yang J, Tanasa B, Li W . lncRNA-dependent mechanisms of androgen-receptor-regulated gene activation programs. Nature. 2013; 500(7464):598-602. PMC: 4034386. DOI: 10.1038/nature12451. View